Mizuho raises Haemonetics stock price target on plasma strength
Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.
How this was made
The 30-second read
Why it matters
The earnings beat and higher price targets provide a fresh catalyst for short‑term buying interest.
Market read
New earnings data and analyst upgrades create immediate trading opportunity.
What to watch
CSL contribution expected later may boost future growth but is not yet priced.
Background
Haemonetics reported Q2 earnings that beat estimates, prompting analyst target upgrades.
Ticker impact
Mizuho raised its price target to $165 and BTIG to $142 after Haemonetics reported an earnings beat.
likely upside as the market prices in the higher targets
Target raises and earnings beat provide fresh positive catalyst.
Market effects
Strong plasma‑technology performance may lift related medical device peers.
U.S. healthcare sector could see modest gains.
Limited to U.S. listed medical‑device space.
Counterpoint
The margin guidance downgrade and higher spending could temper upside.
Key entities
- AnalystMizuho
Raised price target to $165, Outperform rating.
- AnalystBTIG
Raised price target to $142, Buy rating.
